Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
Primary Purpose
Atrial Fibrillation
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
catheter ablation
Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
Sponsored by
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
- 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial
Exclusion Criteria:
- 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman
Sites / Locations
- Renmin Hospital of Wuhan UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Antiarrythmic Drugs
ablation
Arm Description
Outcomes
Primary Outcome Measures
Number of participants with all-cause death
Number of participants with all-cause death
Number of participants with all-cause death
Number of participants with all-cause death
severe blooding complications
severe blooding complications
severe blooding complications
severe blooding complications
cardio-cerebrovascular complications
cardio-cerebrovascular complications
cardio-cerebrovascular complications
cardio-cerebrovascular complications
Number of participants with cardiovascular death events
Number of participants with cardiovascular death events
Number of participants with cardiovascular death events
Number of participants with cardiovascular death events
Secondary Outcome Measures
recurrence of atrial arrhythmias (AF, AFL, AT)
recurrence of atrial arrhythmias (AF, AFL, AT)
recurrence of atrial arrhythmias (AF, AFL, AT)
recurrence of atrial arrhythmias (AF, AFL, AT)
resource utilization and costs
resource utilization and costs
resource utilization and costs
Full Information
NCT ID
NCT01341353
First Posted
April 21, 2011
Last Updated
April 21, 2011
Sponsor
Wuhan University
Collaborators
Capital Medical University, Peking Union Medical College, Guangdong Provincial People's Hospital, Nanjing Medical University, West China Hospital, Dalian Medical University, Shanghai Chest Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01341353
Brief Title
Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
Official Title
Atrial Fibrillation Therapy: A Multi-Center Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2011
Overall Recruitment Status
Unknown status
Study Start Date
April 2011 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2015 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Wuhan University
Collaborators
Capital Medical University, Peking Union Medical College, Guangdong Provincial People's Hospital, Nanjing Medical University, West China Hospital, Dalian Medical University, Shanghai Chest Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1800 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Antiarrythmic Drugs
Arm Type
Active Comparator
Arm Title
ablation
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
catheter ablation
Intervention Description
circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
Intervention Type
Drug
Intervention Name(s)
Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
Primary Outcome Measure Information:
Title
Number of participants with all-cause death
Time Frame
3 month
Title
Number of participants with all-cause death
Time Frame
12 month
Title
Number of participants with all-cause death
Time Frame
24 month
Title
Number of participants with all-cause death
Time Frame
36 month
Title
severe blooding complications
Time Frame
3 month
Title
severe blooding complications
Time Frame
12 month
Title
severe blooding complications
Time Frame
24 month
Title
severe blooding complications
Time Frame
36 month
Title
cardio-cerebrovascular complications
Time Frame
3 month
Title
cardio-cerebrovascular complications
Time Frame
12 month
Title
cardio-cerebrovascular complications
Time Frame
24 month
Title
cardio-cerebrovascular complications
Time Frame
36 month
Title
Number of participants with cardiovascular death events
Time Frame
3 month
Title
Number of participants with cardiovascular death events
Time Frame
12 month
Title
Number of participants with cardiovascular death events
Time Frame
24 month
Title
Number of participants with cardiovascular death events
Time Frame
36 month
Secondary Outcome Measure Information:
Title
recurrence of atrial arrhythmias (AF, AFL, AT)
Time Frame
3 month
Title
recurrence of atrial arrhythmias (AF, AFL, AT)
Time Frame
12 month
Title
recurrence of atrial arrhythmias (AF, AFL, AT)
Time Frame
24 month
Title
recurrence of atrial arrhythmias (AF, AFL, AT)
Time Frame
36 month
Title
resource utilization and costs
Time Frame
12 month
Title
resource utilization and costs
Time Frame
24 month
Title
resource utilization and costs
Time Frame
36 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial
Exclusion Criteria:
1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cong xin Huang, doctor
Phone
13907131546
Email
huangcongxin@yahoo.com.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cong xin Huang, doctor
Organizational Affiliation
Renmin Hospital of Wuhan University
Official's Role
Study Chair
Facility Information:
Facility Name
Renmin Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cong xin Huang, doctor
Phone
13907131546
Email
huangcongxin@yahoo.com.cn
First Name & Middle Initial & Last Name & Degree
cong xin Huang, doctor
12. IPD Sharing Statement
Learn more about this trial
Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
We'll reach out to this number within 24 hrs